Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Merger or Acquisition (November 2022)
14 slides from Indivior Pharmaceuticals's merger presentation, Nov 14, 2022
Slide 1: Strengthening and Extending Leadership in Addiction Treatment & Science
STRENGTHENING AND EXTENDING LEADERSHIP IN Addiction Treatment & Science November 14, 2022
Slide 2: Forward-looking statements
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE Forward-looking statements Statements included in this presentation that are not a description of historical facts are forward-looking statements. Words or phrases such as “believe,” “may,” “could,” “will,” “estimate,” “continue
Slide 3: Important Information for Investors and Stockholders
IMPORTANT INFORMATION FOR INVESTORS AND STOCKHOLDERS This communication does not constitute a solicitation of any vote or approval. Opiant intends to file with the SEC and mail to its stockholders a definitive proxy statement in connection with the proposed transactions. OPIANT’S STOCKHOLDERS ARE UR
Slide 4: Business Overview: Opiant Pharmaceuticals
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE Business Overview: Opiant Pharmaceuticals SYMBOL NASDAQ: OPNT (www.opiant.com) COMPANY STRATEGY Develops pharmacotherapies for substance use disorders and drug overdose NUMBER OF EMPLOYEES 40+ HEADQUARTERS Santa Monica, CA ASSET
Slide 5: Compelling strategic & financial rationale
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE Compelling strategic & financial rationale Strategic Rationale Financial Rationale Strengthens and Extends Indivior’s Leadership in OPNT003 Potential Annual NR of $150m to $250m Addiction Treatment and Science Provides a New and
Slide 6: A leading addiction treatment and science platform upon closing
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE A leading addiction treatment and science platform upon closing Leading Addiction Treatments Across the Proven Addiction-Focused Commercial Strong Addiction Science, Continuum of Care Capabilities Development & Advocacy (Commerc
Slide 7: OPNT003 addresses the current wave of US opioid overdose driven by synthetics
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE OPNT003 addresses the current wave of US opioid overdose being driven by synthetics 12 Month-ending Reported Provisional Number of Drug Overdose Deaths by Drug or Drug Class (CDC data) OPNT003 (nasal nalmefene) (May 2019 - May 2
Slide 8: Synthetic opioids are challenging current treatment options
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE Synthetic opioids are challenging current treatment options “Most of the crews Naloxone has a Multiple, sequential NIH leadership has are having to use shorter half-life than all but the most short- doses of naloxone are proving
Slide 9: Scientific evidence confirms OPNT003's potential to improve and sustain reversal of opioid overdose
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE Scientific evidence confirms OPNT003’s potential to improve and sustain reversal of opioid overdose OPNT003 compared with 4mg nasal naloxone OPNT003 vs. 4mg nasal naloxone(5) OPNT0003 (3mg) Naloxone (4mg) Affinity at μ opioid re
Slide 10: NDA submission under Fast-Track designation expected Q4 2022; expected approval Q3 2023
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE NDA submission under “Fast-Track” designation expected Q4 2022; expected approval Q3 2023 Key development activities funded by NIDA and BARDA PK Study Q4 Q3 2022 2023 Pilot Non-clinical PD Data Expected Expected Pharmacokinetic
Slide 11: OPNT003 is complementary to SUBLOCADE and Patient Recovery
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE OPNT003 is complementary to SUBLOCADE® and Patient Recovery A vision for a continuum of care with SUBLOCADE®, OPNT003 and psychosocial support Addiction is a chronic and relapsing disease of the brain SUBLOCADE® helps break the
Slide 12: OPNT002 – Attractive opportunity as an "as needed" nasal spray
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE OPNT002 – Attractive opportunity with the potential to become “as needed” nasal spray when patient anticipates drinking or craving alcohol Summary of Phase 1 PK data Naltrexone Blood Levels Rapid nasal absorption of OPNT002 vs.
Slide 13: Transaction summary
STRENGTHENING AND EXTENDING LEADERSHIP IN ADDICTION TREATMENT & SCIENCE Transaction summary* EQUITY PURCHASE PRICE ~$145 million ($20.00 per Opiant share), plus contingent value rights potentially worth up to an additional $8.00 per Opiant share, subject to achievement of certain milestones CONSIDER
Slide 14: sé INDIVIOR’
sé INDIVIOR’